AXL and cancer: Lower sensitivity to erlotinib treatment in NSCLC cells can be restored by combining erlotinib with autophagy‐inducing drug rapamycin.[34] While targeting AXL can abrogate autophagic flux and induce immunogenic cell death in EGFR‐TKI resistant cancer cells.[35] In this study, we identified the different autophagy levels between AZD9291‐resistant and AZD9291‐sensitive cell lines with both EGFR sensitive and T790M mutation, suggesting a protective role of autophagy in AZD9291 treatment.